Precision Medicine Group

Algorics Inc is a Houston-based company that specializes in developing clinical analytics solutions and software for the life sciences industry. Founded in 1980, Algorics focuses on enhancing the efficiency of clinical trials for bio-pharma companies and contract research organizations (CROs) by providing real-time data insights. Its flagship product, the Acuity platform, is a regulatory-compliant, cloud-based solution that transforms data into actionable knowledge, enabling users to evaluate drugs, diseases, and performance effectively. The company also offers Acuity RBM, which facilitates collaboration among teams to identify risks and develop mitigation strategies, and Acuity Insights, which aims to reduce regulatory risks while improving quality and compliance through real-time insights. In August 2015, Algorithm, Inc. rebranded to Algorics Inc, and as of February 2018, it operates as a subsidiary of OmniComm Systems, Inc.

Project Farma is a consulting firm that specializes in providing strategic and execution services to healthcare companies throughout the entire pharmaceutical and medical device supply chain. The firm focuses on biomanufacturing, offering expertise in capital projects, technology transfers, facility construction, strategy development, and regulatory compliance. By delivering tailored solutions, Project Farma assists clients in navigating the complexities of the healthcare industry, ensuring efficient operations and adherence to industry standards.

ProMedDx is a contract research organization specializing in the delivery of human biologics and supporting clinical services. The company provides annotated biospecimens and a range of related services, including patient recruitment, prospective specimen collection, biospecimen procurement, bioprocessing, biostorage, and clinical study monitoring. By offering these services, ProMedDx facilitates access for the biobanking industry to manage global biospecimen resources and connect directly with patients.

Stern Investor Relations, Inc. is an investor relations firm based in New York, specializing in the biotechnology and healthcare sectors. Founded in 1998, the company focuses on supporting entrepreneurial companies by offering a range of services including investor and industry research, material assessment, opportunity analysis, strategy development, ESG advising, and executive education. Stern Investor Relations provides tailored counsel, leveraging its comprehensive knowledge of the technical, regulatory, and financial aspects of the dynamic life sciences industry. The firm closely monitors industry trends to deliver data-driven insights, assisting companies in preparing for public offerings and offering ongoing support throughout their growth. As of December 2018, Stern Investor Relations operates as a subsidiary of Precision Medicine Group, Inc.

ApoCell, Inc. is a specialty clinical research company based in Houston, Texas, with additional offices and laboratories in Leipzig, Germany. Founded in 2004, ApoCell focuses on biomarker development, analysis, and diagnostics, specializing in the identification of rare circulating cells such as circulating tumor cells (CTCs). The company provides a range of clinical trial support services across various therapeutic areas, including oncology, diabetes, inflammation, and chronic kidney disease. Its offerings encompass sample logistics, project management, biomarker consultation, and companion diagnostics. ApoCell employs advanced liquid biopsy technology to detect and isolate biomarkers from whole blood, enabling less invasive and more cost-effective diagnostic options compared to traditional tumor biopsies. The firm also develops customized biomarker assays, supporting the validation and feasibility of various reagents for use in clinical studies. ApoCell serves pharmaceutical and biotechnology companies, as well as academic institutions globally, and maintains a strategic partnership with Cancer Genetics, Inc.

Epiontis, founded in 2003 by Dr. Sven Olek and Dr. Ulrich Hoffmueller, is a biotechnology company based in the Science and Technology Park Adlershof in Berlin, Germany. The company specializes in molecular diagnostics, offering immune cell monitoring services and customized development of epigenetic assays. Epiontis's innovative epigenetic assay format accurately identifies and quantifies various cell types, primarily focusing on the monitoring of immune cells in research and clinical studies related to autoimmune diseases, infectious diseases, and cancer. Their portfolio includes established diagnostic assays for regulatory T cells and tumor-infiltrating lymphocytes, along with several other epigenetic assays in development. Additionally, Epiontis provides tailored immunomonitoring assay development services aimed at supporting drug companies in the immuno-oncology and autoimmune sectors, enabling them to accelerate the market introduction of effective therapies.

Applied Immunology is a contract research laboratory that specializes in providing services to support the development of biological therapeutics and diagnostics. The company focuses on cell-based and bioanalytical assays, which are essential for the evaluation of biologics and for clinical immune monitoring of therapeutic products. Through its expertise in applied immunology, the company aids clients in advancing their therapeutic and diagnostic innovations, ensuring they meet the necessary scientific and regulatory standards.